{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:19:55Z","timestamp":1790630395503,"version":"4.1.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"\n Background:<\/jats:title>\n We aimed to evaluate the therapeutic effect of additional ursodeoxycholic acid (UDCA) with mesalazine, compared to mesalazine alone in patients with ulcerative colitis (UC). The mechanism was evaluated by monitoring the changes of IL-23-IL-17 axis and the intestinal microflora.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n In this prospective, single center study, patients with UC were randomly assigned to the Mesalazine group (n=20) or the UDCA + Mesalazine group (\n n<\/jats:italic>\n =20). Mayo score and Inflammatory Bowel Disease Questionnaire (IBDQ), and fecal samples for 16S rRNA sequencing and blood samples for IL-23 and IL-17 ELISA were collected for analysis.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Mayo scores and IBDQ score of the UDCA + Mesalazine group were significantly better than those of the Mesalazine group (\n P<\/jats:italic>\n = 0.015 and\n P<\/jats:italic>\n < 0.001, respectively). At post-treatment week 4, IL-23 and IL-17 levels were significantly lower in the UDCA + Mesalazine group compared to those in the Mesalazine group (both\n P<\/jats:italic>\n < 0.038). In patients with UC after treatment,\n Firmicutes<\/jats:italic>\n in the UDCA + Mesalazine group was higher than those in the Mesalazine group (\n P<\/jats:italic>\n < 0.001). The UDCA + Mesalazine group showed lower percentage of\n Proteobacteria<\/jats:italic>\n compared to those in the Mesalazine group (\n P<\/jats:italic>\n < 0.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Additional UDCA could provide better therapeutic effects than mesalazine alone, possibly due to the change of IL-23 and IL-17 and the proportional distribution of intestinal microflora.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/sjg.sjg_462_20","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T09:56:52Z","timestamp":1617616612000},"page":"149-157","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":26,"title":["Clinical effects of ursodeoxycholic acid on patients with ulcerative colitis may improve via the regulation of IL-23-IL-17 axis and the changes of the proportion of intestinal microflora"],"prefix":"10.4103","volume":"27","author":[{"given":"Zhengjun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longke","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20240829","doi-asserted-by":"crossref","first-page":"e0124211","DOI":"10.1371\/journal.pone.0124211","article-title":"Health-related quality of life in Chinese patients with mild and moderately active ulcerative colitis","volume":"10","author":"Zheng","year":"2015","journal-title":"PLoS One"},{"key":"R2-6-20240829","doi-asserted-by":"crossref","first-page":"G716","DOI":"10.1152\/ajpgi.00472.2010","article-title":"Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease","volume":"300","author":"Danese","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R3-6-20240829","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/MIB.0000000000000714","article-title":"Cytokine networks and T-cell subsets in inflammatory bowel diseases","volume":"22","author":"Chen","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"R4-6-20240829","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1142\/S0192415X17500550","article-title":"The mixture of anemarrhena asphodeloides and coptis chinensis attenuates high-fat diet-induced colitis in mice","volume":"45","author":"Lim","year":"2017","journal-title":"Am J Chin Med"},{"key":"R5-6-20240829","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev-med-051914-021944","article-title":"Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases","volume":"67","author":"Fragoulis","year":"2016","journal-title":"Annu Rev Med"},{"key":"R6-6-20240829","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1684\/ecn.2015.0363","article-title":"Usefulness of selected laboratory markers in ulcerative colitis","volume":"26","author":"Ma\u0144kowska-Wierzbicka","year":"2015","journal-title":"Eur Cytokine Netw"},{"key":"R7-6-20240829","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/gut.2007.135053","article-title":"IL23 differentially regulates the Th1\/Th17 balance in ulcerative colitis and Crohn's disease","volume":"57","author":"Kobayashi","year":"2008","journal-title":"Gut"},{"key":"R8-6-20240829","first-page":"199","article-title":"The impact of thiopurine-S-methyltransferase genotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases","volume":"114","author":"Hlavaty","year":"2013","journal-title":"Bratisl Lek Listy"},{"key":"R9-6-20240829","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/apt.15402","article-title":"Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: Myelotoxicity and hepatotoxicity rarely affect maintenance treatment","volume":"50","author":"Kreijne","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R10-6-20240829","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/labinvest.2014.117","article-title":"Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death","volume":"94","author":"Laukens","year":"2014","journal-title":"Lab Invest"},{"key":"R11-6-20240829","doi-asserted-by":"crossref","first-page":"11874","DOI":"10.1038\/s41598-018-30349-1","article-title":"Ursodeoxycholic acid improves liver function via phenylalanine\/tyrosine pathway and microbiome remodelling in patients with liver dysfunction","volume":"8","author":"Kim","year":"2018","journal-title":"Scientific Reports"},{"key":"R12-6-20240829","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy","volume":"67","author":"Tang","year":"2018","journal-title":"Gut"},{"key":"R13-6-20240829","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/cid\/ciy568","article-title":"Repurposing an old drug for a new epidemic: Ursodeoxycholic acid to prevent recurrent clostridioides difficile infection","volume":"68","author":"Webb","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R14-6-20240829","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2362.2000.00615.x","article-title":"Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes","volume":"30","author":"Benz","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"R15-6-20240829","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gutjnl-2012-302578","article-title":"Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases","volume":"62","author":"Duboc","year":"2013","journal-title":"Gut"},{"key":"R16-6-20240829","first-page":"4538","article-title":"Analysis of changes in intestinal flora and intravascular inflammation and coronary heart disease in obese patients","volume":"15","author":"Li","year":"2018","journal-title":"Exp Ther Med"},{"key":"R17-6-20240829","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.21873\/anticanres.12664","article-title":"Severe defects in the macrophage barrier to gut microflora in inflammatory bowel disease and colon cancer","volume":"38","author":"Rubio","year":"2018","journal-title":"Anticancer Res"},{"key":"R18-6-20240829","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/gutjnl-2015-309990","article-title":"The gut microbiota and host health: A new clinical frontier","volume":"65","author":"Marchesi","year":"2016","journal-title":"Gut"},{"key":"R19-6-20240829","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/path.5236","article-title":"Integration of microbiology, molecular pathology, and epidemiology: A new paradigm to explore the pathogenesis of microbiome-driven neoplasms","volume":"247","author":"Hamada","year":"2019","journal-title":"J Pathol"},{"key":"R20-6-20240829","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/ecco-jcc\/jjx075","article-title":"Genetic mouse models with intestinal-specific tight junction deletion resemble an ulcerative colitis phenotype","volume":"11","author":"Stremmel","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R21-6-20240829","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000486858","article-title":"Phospholipase A(2) of microbiota as pathogenetic determinant to induce inflammatory states in ulcerative colitis: Therapeutic implications of phospholipase A(2) inhibitors","volume":"2","author":"Stremmel","year":"2018","journal-title":"Inflamm Intest Dis"},{"key":"R22-6-20240829","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13539-012-0091-5","article-title":"Ursodeoxycholic acid and its emerging role in attenuation of tumor growth in gastrointestinal malignancies","volume":"3","author":"Kapoor","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R23-6-20240829","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"R24-6-20240829","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"key":"R25-6-20240829","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nrgastro.2016.128","article-title":"Current best practice for disease activity assessment in IBD","volume":"13","author":"Walsh","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R26-6-20240829","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/apt.15005","article-title":"Systematic review with network meta-analysis: The impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life","volume":"48","author":"Paschos","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R27-6-20240829","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.3390\/ijms20143394","article-title":"Th17 cells and the IL-23\/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases","volume":"20","author":"Bunte","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R28-6-20240829","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2567.2011.03454.x","article-title":"Interleukin-23 and T helper 17-type responses in intestinal inflammation: From cytokines to T-cell plasticity","volume":"133","author":"Morrison","year":"2011","journal-title":"Immunology"},{"key":"R29-6-20240829","first-page":"5498","article-title":"Serum IL-17 and IL-6 increased accompany with TGF-\u03b2 and IL-13 respectively in ulcerative colitis patients","volume":"7","author":"Feng","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"R30-6-20240829","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J Biol Chem"},{"key":"R31-6-20240829","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J Clin Invest"},{"key":"R32-6-20240829","first-page":"465","article-title":"Andrographolide presents therapeutic effect on ulcerative colitis through the inhibition of IL-23\/IL-17 axis","volume":"10","author":"Zhu","year":"2018","journal-title":"Am J Transl Res"},{"key":"R33-6-20240829","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.clim.2018.09.001","article-title":"Importance of TLR9-IL23-IL17 axis in inflammatory bowel disease development: Gene expression profiling study","volume":"197","author":"Dragasevic","year":"2018","journal-title":"Clin Immunol"},{"key":"R34-6-20240829","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nri3608","article-title":"Intestinal epithelial cells: Regulators of barrier function and immune homeostasis","volume":"14","author":"Peterson","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"R35-6-20240829","doi-asserted-by":"crossref","first-page":"6612","DOI":"10.4049\/jimmunol.1000041","article-title":"Human intestinal lamina propria CD1c+dendritic cells display an activated phenotype at steady state and produce IL-23 in response to TLR7\/8 stimulation","volume":"184","author":"Dillon","year":"2010","journal-title":"J Immunol"},{"key":"R36-6-20240829","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1053\/j.gastro.2007.03.104","article-title":"Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice","volume":"132","author":"Elson","year":"2007","journal-title":"Gastroenterology"},{"key":"R37-6-20240829","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/ismej.2013.80","article-title":"Dysbiosis in inflammatory bowel diseases: The oxygen hypothesis","volume":"7","author":"Rigottier-Gois","year":"2013","journal-title":"Isme J"},{"key":"R38-6-20240829","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.freeradbiomed.2016.09.022","article-title":"Oxygen as a driver of gut dysbiosis","volume":"105","author":"Rivera-Ch\u00e1vez","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"R39-6-20240829","doi-asserted-by":"crossref","first-page":"16731","DOI":"10.1073\/pnas.0804812105","article-title":"Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients","volume":"105","author":"Sokol","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R40-6-20240829","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.MIB.0000200323.38139.c6","article-title":"Specificities of the fecal microbiota in inflammatory bowel disease","volume":"12","author":"Sokol","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"R42-6-20240829","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.tibtech.2015.06.011","article-title":"Proteobacteria: Microbial signature of dysbiosis in gut microbiota","volume":"33","author":"Shin","year":"2015","journal-title":"Trends Biotechnol"},{"key":"R43-6-20240829","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1128\/JCM.01004-06","article-title":"Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis","volume":"44","author":"Gophna","year":"2006","journal-title":"J Clin Microbiol"},{"key":"R44-6-20240829","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1099\/jmm.0.021170-0","article-title":"Transcriptional activity of the dominant gut mucosal microbiota in chronic inflammatory bowel disease patients","volume":"59","author":"Rehman","year":"2010","journal-title":"J Med Microbiol"},{"key":"R45-6-20240829","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.chom.2017.01.005","article-title":"Microbial Respiration and formate oxidation as metabolic signatures of inflammation-associated dysbiosis","volume":"21","author":"Hughes","year":"2017","journal-title":"Cell Host Microbe"},{"key":"R46-6-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mib.2017.07.003","article-title":"Dysbiotic Proteobacteria expansion: A microbial signature of epithelial dysfunction","volume":"39","author":"Litvak","year":"2017","journal-title":"Curr Opin Microbiol"},{"key":"R47-6-20240829","doi-asserted-by":"crossref","first-page":"9351507","DOI":"10.1155\/2017\/9351507","article-title":"Proteobacteria: A common factor in human diseases","volume":"2017","author":"Rizzatti","year":"2017","journal-title":"BioMed Res Int"},{"key":"R49-6-20240829","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.dld.2018.03.016","article-title":"Exploring bacteroidetes: Metabolic key points and immunological tricks of our gut commensals","volume":"50","author":"Gibiino","year":"2018","journal-title":"Dig Liver Dis"},{"key":"R50-6-20240829","doi-asserted-by":"crossref","first-page":"17026","DOI":"10.1038\/nmicrobiol.2017.26","article-title":"An insider's perspective: Bacteroides as a window into the microbiome","volume":"2","author":"Wexler","year":"2017","journal-title":"Nat Microbiol"},{"key":"R51-6-20240829","doi-asserted-by":"crossref","first-page":"5828959","DOI":"10.1155\/2016\/5828959","article-title":"Lower level of bacteroides in the gut microbiota is associated with inflammatory bowel disease: A meta-analysis","volume":"2016","author":"Zhou","year":"2016","journal-title":"Biomed Res Int"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.SJG_462_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:24:11Z","timestamp":1787844251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.SJG_462_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_462_20","relation":{},"ISSN":["1319-3767"],"issn-type":[{"value":"1319-3767","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}